# OptimizeRx to Participate in the 15th Annual ROTH Technology Conference

- Published: 2026-11-16
- Author: [Healthcare News](https://healthcarenews.io/author/healthcarenews-io.md)
- Topics: [News](https://healthcarenews.io/news.md)
- Source: https://healthcarenews.io/news/optimizerx-to-participate-in-the-15th-annual-roth-technology-conference/
- Publication: Healthcare News
- Publisher: Connectively (Terkel, Inc.)
- Editorial policy: https://healthcarenews.io/editorial-policy/

WALTHAM, Mass., Nov. 16, 2026 [(GLOBE NEWSWIRE)](https://www.globenewswire.com) -- <a href="https://www.globenewswire.com/Tracker?data=q0fWkfgbJzlaQ2RMnpt-4IPQ__-WubYMKjGaQScZqT8vdONd2OCU7RNwjD3gkAzoK8ju2TwpYsIg6Gfa_HdPHaY8PR5juLF_qLh2iahULIM=" rel="nofollow">OptimizeRx Corp</a>. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients at critical decision points, today announced that management will participate in the 15th Annual ROTH Technology Conference taking place on Wednesday, November 18, 2026, in New York, NY.

To request a meeting or for more details about the conference please reach out to your institutional contact.

**About OptimizeRx**

OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative AI-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood® Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.

Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.

For more information, follow the Company on <a href="https://www.globenewswire.com/Tracker?data=YXzAYz7TyhokB5aV-Fjrq2Wlvp1JzUrtlOZLG5FNLhvPvZM_3zhkBFfJAr8uVBrnK4HI8POM8OqMPprkoLBZXPNbmcKSQcVUvq9ytTUP01yEJgmBFJthxxzFqpYl_nm9qZjc0u627WNH4-76LAFanKxGhJ-WMGzXq-3ETM5T0EE9au14pnZCR8M85-UtZtFWNrYpv912os8fy0PSZTcbRg==" rel="nofollow">X</a>, <a href="https://www.globenewswire.com/Tracker?data=6jqcZbifdjJExnVVAf3mg_nTduJTTUZqeoMyQhr6GYVNKP8cAkzH_aSYwMkIpCxflkYsChieiUu12iRMBLE0m6L7QmqSKJwZNj_foYvaVceRWRufqyrXj5nRZsQhiHseSRcb3hL27bwvV85bR6-QSiRKgLZO3PWrpxfzF5t9SVQVTGYapbdr42r2c-ExjxfmzlPcT8RN8RjjTyRTRuChgvNbrYT-BVrRGUMu6ZygJE0Lns85JXhStJRPtF3lozTe" rel="nofollow">LinkedIn</a> or visit <a href="https://www.globenewswire.com/Tracker?data=MOOfrUXFCBwIufS7E6SS_upsJcqbx8WvqULOE0JAyo85k_Exc-XLU_nknkFlQuxF5rGPJu4PCaC_ycvJE9HbpdT4wXVYWipttZIFHdY4k5bAtYPDKsop99SZj10ezqcyeYuKOvh4e7ksfx5z4Bn7iferziJo8MF4NG_ZoZ_jaxfpX7V_6QVwfGWqITZ0j9fkMNIFNNhjOj5k3qXDddC0MBA8XRk4uTdCCoI6wtP_XoOMZRpt4OvoViqGiAX4fqD-LU6DZgP2WdtolWzFlYBBeQ==" rel="nofollow">www.optimizerx.com</a>.

**OptimizeRx Contact**  
Andy D’Silva, Chief Business Officer  
<a href="https://www.globenewswire.com/Tracker?data=p8wCqiAfVwl1HEYcrqTcfOnUKiLy6AvQbXfywzDxrvj5kNo_NVAmAnaFEvwXiqiUqtUxlMLSW3Fb8TS_9TqSLKLztZkAflDMRX08TLmeafKRJjEXZnjKvJWGAjcnMVWE7xGYh9AQqanwMSLPH_VIda85itbFdJ9uIyb6MoSE4Z9HZDhT2jft_txibPmnSsn61hBOtM-ne8OaqzT0KAuZiS60UF4irNm3RJbhQDDvD2HxXqQvFxkGDdNTD-2di-1oF1VgykWsV3jexZpPtPmWwA==" rel="nofollow">adsilva@optimizerx.com</a>

**Investor Relations Contact**  
Douglas Farrell  
LifeSci Advisors, LLC  
<a href="https://www.globenewswire.com/Tracker?data=NCPIxuajfmZ7y4_fvAjpnv5n44xaHewDtiJbWnW80IFyWmH_GdLcrYnoQXRawwm2GGv_ZXtaZO1_iIJ-xddEqfyU9qEvHWAGlYHJH0w6xatPAP7VrHMbIPJNSCd0ITae5VpTb9U3oaPHC4geWRtIsUjdKLQSQ7GXyCKvhB16eQy6LD80P3Q4i3JjN0mpJ6RKT9sPbpbOQq2G7ThO8UL_6lU5h1pgeZQlS0WwVhDJkSytUs4oWyTMA2fjh-Hr0Wz-V3NMY69uE_bR108T6C7qyTBQtsypVBSQavOVciQARsY8f45muH_RwMDkoDncm_O8" rel="nofollow">dfarrell@lifesciadvisors.com</a>

  
![](https://ml.globenewswire.com/media/Njc4MGQ4NWQtNTQ1Zi00YWNiLTk2NzYtYWQwMTE3YmZiMmVlLTEwNjE0NTUtMjAyNi0xMS0xNi1lbg==/tiny/OptimizeRx-Corporation.png)

## Related

- [Clearmind Achieves Full Enrollment for Part C in CMND-100 Phase I/IIa Trial, Marking Key Clinical Milestone](https://healthcarenews.io/news/clearmind-achieves-full-enrollment-for-part-c-in-cmnd-100-phase-i-iia-trial-marking-key-cl.md)
- [Rein Therapeutics Announces Preliminary Blinded Phase 2 RENEW Data Showing Encouraging Lung Function Trends in Patients with Idiopathic Pulmonary Fibrosis and Reports Third Quarter 2026 Financial Results](https://healthcarenews.io/news/rein-therapeutics-announces-preliminary-blinded-phase-2-renew-data-showing-encouraging-lun.md)
- [Surgery Partners, Inc. Announces Commencement of Consent Solicitation Relating to Surgery Center Holdings, Inc.’s 7.250% Senior Notes due 2032](https://healthcarenews.io/news/surgery-partners-inc-announces-commencement-of-consent-solicitation-relating-to-surgery-ce.md)
- [Moleculin Biotech Reports Third Quarter 2026 Financial Results as Pivotal MIRACLE Trial Advances Toward Key Q1 2027 Data Readout](https://healthcarenews.io/news/moleculin-biotech-reports-third-quarter-2026-financial-results-as-pivotal-miracle-trial-ad.md)
